Cambridge Design Partnership has announced the development of a new novel uterine balloon tamponade (UBT) to control postpartum haemorrhage (PPH) in low-resource settings in developing countries.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The UBT is designed to tackle life-threatening situations experienced by women after childbirth.

PPH is a condition of severe bleeding that occurs within 24 hours of childbirth, which is also one of the leading causes of maternal mortality across developing parts of the world.

According to Cambridge, if the right equipment is used at the right time to control PPH, many lives can be saved.

"The UBT is designed to tackle life-threatening situations experienced by women after childbirth."

The World Health Organisation (WHO) included UBT as a treatment for PPH in its 2012 recommendations. However, each commercially available UBT could cost up to $200, making it less accessible to people.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Condom catheter is also used as an alternative to UBT, but placement of the device has to be done carefully by skilled professionals.

Developed to narrow the gap between condom catheters and $200 UBTs, the new device has a novel intuitive design and is safe to be used even by less experienced healthcare workers.

Cambridge Design Partnership human centred design specialist Lucy Sheldon said: "To be effective in low resource settings, medical products such as UBTs must be affordable and available; optimised for the intended conditions of distribution, storage, and use.

"To meet these needs, we applied a human centred approach to the innovation process, combining expertise in human factors, risk management and interaction design, to the development of our device.

"Our aim was to maximise usability in the hands of minimally trained birth assistants and lower the overall costs of the intervention through reducing the medical professionals, equipment and training required to safely and effectively use the device, to ultimately save lives."


Image: Sub-Saharan African countries are said to carry the highest risks in terms of maternal and infant mortality and health. Photo: courtesy of Steve Evans.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact